-+ 0.00%
-+ 0.00%
-+ 0.00%

Arvinas Phase 1 trial shows ARV-102 achieves at least 50% LRRK2 reduction in Parkinson’s CSF by day 14

Reuters·03/18/2026 11:04:46

Please log in to view news